Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Cancer of the Breast
Interventions: DEVICE: DiviTum® TKa assay|OTHER: Study Care Plans
Sponsor: Washington University School of Medicine
Collaborators: Biovica